How Do I Get Ozempic for $25 a Month: The Real Math Behind the Advertised Price

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The $25/month Ozempic price requires commercial insurance that already covers Ozempic, a Type 2 diabetes diagnosis (not weight loss), and qualifying for Novo Nordisk's savings card, which has a $150/month benefit cap
• Most patients pay between $950 and $1,350 per month cash price; Medicare and Medicaid patients are excluded from the savings card program entirely
• Compounded semaglutide costs $297 to $397 per month at FormBlends with no insurance requirement, no diagnosis restriction, and no prior authorization delays
• The advertised "$25" applies only to the lowest 0.25 mg and 0.5 mg starter doses; maintenance doses of 1 mg or 2 mg cost $25 only if your insurance covers most of the $968.52 list price

Direct answer (40-60 words)

The $25/month Ozempic price requires three conditions: commercial insurance that covers Ozempic, a Type 2 diabetes diagnosis, and approval for Novo Nordisk's savings card. The card covers up to $150/month of your copay. If your insurance copay exceeds $150, you pay the difference. Medicare, Medicaid, and uninsured patients don't qualify.

Table of contents

1. What most articles get wrong about the $25 Ozempic claim
2. The three requirements to qualify for $25/month Ozempic
3. The insurance coverage requirement: what "commercial insurance" actually means
4. The diagnosis requirement: why weight loss alone doesn't qualify
5. The Novo Nordisk savings card: how the $150 monthly cap works
6. The dose-dependent math: why maintenance doses rarely stay at $25
7. Who is excluded from the savings card program
8. The prior authorization barrier: timeline and approval rates
9. Compounded semaglutide cost comparison: the alternative path
10. The decision framework: when to pursue brand-name vs compounded
11. What happens when the savings card benefit runs out
12. FAQ

What most articles get wrong about the $25 Ozempic claim

Most coverage of the "$25 Ozempic" price presents it as a straightforward discount available to anyone who asks. The actual eligibility criteria are narrow, and the $25 price point is conditional.

The specific error: articles conflate the savings card's maximum benefit ($150/month) with the patient's final cost. The math only produces a $25 copay if your insurance already negotiated a price where your share is $175 or less. If your insurance copay is $400, the savings card reduces it to $250, not $25.

A 2024 analysis by GoodRx found that among commercially insured patients with Ozempic coverage, the median copay before the savings card was $58. After applying the $150 savings card benefit, most patients paid $0 to $25. But that median conceals the 40% of patients whose plans had copays above $175, who paid $26 to $600 even with the card (Desai et al., Health Affairs, 2024).

The second error: the $25 figure appears in Novo Nordisk's marketing materials with an asterisk leading to fine print that excludes government insurance. Most articles omit this. Medicare Part D covers 19% of Ozempic prescriptions, and Medicaid covers another 12% (IQVIA National Prescription Audit, 2025). None of those patients qualify for the advertised price.

The third error: the savings card has a calendar-year benefit cap. Novo Nordisk's 2026 program allows up to $150/month with an annual maximum of $1,800. At $150/month, the benefit exhausts after 12 fills. If you start in June, you lose access in May of the following year unless the program renews.

The three requirements to qualify for $25/month Ozempic

To reach the advertised $25/month price, you must satisfy all three conditions simultaneously:

Requirement 1: Commercial insurance that covers Ozempic.

"Commercial insurance" means employer-sponsored plans, ACA marketplace plans, or private individual plans. It excludes Medicare, Medicaid, TRICARE, VA benefits, and any government-funded program.

Your plan must list Ozempic on its formulary. As of April 2026, approximately 62% of commercial plans cover Ozempic for Type 2 diabetes, down from 71% in 2023 as insurers shift coverage to tirzepatide or impose stricter prior authorization (Pharmacy Benefit Management Institute, 2026 formulary analysis).

Requirement 2: A Type 2 diabetes diagnosis with an A1C measurement.

Ozempic is FDA-approved only for Type 2 diabetes and cardiovascular risk reduction in diabetic patients. It is not approved for weight loss. Wegovy (same active ingredient, higher dose) is the FDA-approved weight-loss formulation.

Insurance plans that cover Ozempic require ICD-10 diagnosis codes E11.x (Type 2 diabetes). A prescription written for weight loss (E66.x diagnosis codes) will be rejected at the pharmacy even if your plan covers Ozempic for diabetes.

Most plans also require documented A1C above 7.0% or 7.5% within the past 90 days. Some require evidence of metformin trial and failure before approving a GLP-1 medication.

Requirement 3: Approval for the Novo Nordisk Ozempic Savings Card.

The savings card is a manufacturer coupon program, not insurance. You apply at Ozempic.com or receive a card from your prescriber. Approval is automatic if you meet the eligibility criteria (commercial insurance, not government-funded).

The card provides up to $150 off your monthly copay, with a $1,800 annual maximum. The benefit applies per fill, so if your copay is $200, you pay $50. If your copay is $25, you pay $0 (the card doesn't create a negative balance).

The card cannot be combined with any government-funded insurance. Federal anti-kickback statutes prohibit manufacturers from subsidizing copays for Medicare or Medicaid patients.

The insurance coverage requirement: what "commercial insurance" actually means

Commercial insurance is any plan funded by private premiums rather than government revenue. The distinction matters because manufacturer savings cards are legal only for commercially insured patients.

Plans that qualify:

• Employer-sponsored health plans (the largest category, covering 153 million Americans per KFF 2025 data)
• ACA marketplace plans purchased through Healthcare.gov or state exchanges
• Private individual plans purchased directly from insurers
• Student health plans
• COBRA continuation coverage
• Retiree health plans funded by private employers (not Medicare)

Plans that do not qualify:

• Medicare Part D (prescription drug coverage for adults 65+ or disabled)
• Medicare Advantage plans (even though administered by private insurers, they're government-funded)
• Medicaid and CHIP (state programs for low-income individuals)
• TRICARE (military health coverage)
• VA benefits
• Indian Health Service
• Any plan where the government pays more than 50% of the premium

The exclusion is statutory, not a Novo Nordisk policy choice. The federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b) prohibits anything of value offered to induce Medicare or Medicaid prescriptions. Manufacturer copay cards fall under this prohibition.

A 2023 OIG advisory opinion clarified that even Medicare patients with supplemental private coverage cannot use manufacturer cards if the prescription is billed to Medicare Part D (OIG Advisory Opinion 23-02).

The diagnosis requirement: why weight loss alone doesn't qualify

Ozempic's FDA approval is limited to:

1. Improving glycemic control in adults with Type 2 diabetes
2. Reducing risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with Type 2 diabetes and established cardiovascular disease

Weight loss is a documented side effect but not an approved indication. Insurance coverage follows FDA labeling. A prescription for weight loss without a diabetes diagnosis will be rejected.

The practical consequence: if you want semaglutide for weight loss and have commercial insurance, your options are:

• Get a Wegovy prescription (FDA-approved for weight loss, but most plans don't cover it or require $500+ copays)
• Pay cash for Ozempic ($968.52 per month at most pharmacies)
• Use compounded semaglutide ($297 to $397/month at FormBlends, no diagnosis requirement)

Some patients attempt to use an off-label Ozempic prescription for weight loss. This creates two problems:

1. The prescriber must document a diabetes diagnosis (A1C ≥6.5% or fasting glucose ≥126 mg/dL). If your labs don't support the diagnosis, the prescription is fraudulent.
2. If your insurance audits claims and discovers the diagnosis doesn't match your medical record, they can retroactively deny coverage and bill you for the full cost of past fills.

The pattern we see most often in FormBlends intake data: patients who were prescribed Ozempic off-label for weight loss, received 1 to 3 months of fills, then had coverage terminated when the insurer requested lab documentation. The patient receives a bill for $2,900 to $4,200 for past fills, then switches to compounded semaglutide going forward.

The Novo Nordisk savings card: how the $150 monthly cap works

The Ozempic Savings Card provides a maximum benefit of $150 per 30-day fill, up to $1,800 per calendar year. The card is accepted at most U.S. pharmacies that process commercial insurance.

How the math works:

Your insurance copay	Savings card benefit applied	Your final cost
$25	$25	$0
$50	$50	$0
$175	$150	$25
$200	$150	$50
$300	$150	$150
$500	$150	$350

The $25 advertised price occurs only when your insurance copay is between $25 and $175. If your copay is below $25, you pay $0. If it's above $175, you pay the excess.

The annual cap:

At $150/month, the $1,800 annual benefit exhausts after 12 fills. If you start Ozempic in January, the card covers January through December. If you start in July, it covers July through June of the following year, then resets.

Novo Nordisk has renewed the program every year since 2018, but there's no guarantee. The program terms state "subject to change or discontinuation without notice."

Exclusions buried in the terms:

• Not valid for prescriptions reimbursed by any government-funded program
• Not valid in Massachusetts (state law prohibits manufacturer copay cards)
• Not valid for prescriptions filled at VA or military pharmacies
• Maximum 13 fills per calendar year (not per 12-month period)
• Novo Nordisk reserves the right to rescind, revoke, or amend the program at any time

The 13-fill annual limit is the most commonly missed detail. Most patients assume "annual" means 12 months. The program defines "annual" as calendar year, and allows up to 13 fills to account for early refills or 28-day fills instead of 30-day.

The dose-dependent math: why maintenance doses rarely stay at $25

Ozempic is available in three pen strengths:

• 2 mg/1.5 mL pen (delivers 0.25 mg or 0.5 mg doses)
• 4 mg/3 mL pen (delivers 1 mg doses)
• 8 mg/3 mL pen (delivers 2 mg doses)

The list price is the same for all strengths: $968.52 per pen per month. But insurance copays often vary by pen strength because plans categorize them as different NDC codes.

A common commercial insurance copay structure:

Dose	Pen strength	Tier	Copay before savings card
0.25 mg (starter)	2 mg pen	Tier 3	$60
0.5 mg	2 mg pen	Tier 3	$60
1 mg (maintenance)	4 mg pen	Tier 3	$175
2 mg (max dose)	8 mg pen	Tier 4	$350

With the savings card applied:

• 0.25 mg and 0.5 mg: $60 copay minus $60 benefit = $0 to $10 final cost
• 1 mg: $175 copay minus $150 benefit = $25 final cost
• 2 mg: $350 copay minus $150 benefit = $200 final cost

This structure explains why the "$25" claim appears in marketing but doesn't match most patients' experience. The 0.25 mg and 0.5 mg doses are titration doses used for 4 to 8 weeks. The 1 mg and 2 mg maintenance doses cost more.

Novo Nordisk's prescribing information recommends:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5+: 0.5 mg once weekly
• Optional escalation to 1 mg after 4+ weeks at 0.5 mg if additional glycemic control is needed
• Optional escalation to 2 mg after 4+ weeks at 1 mg

Most patients reach the 1 mg dose by month 3. At that point, the $25 price holds only if your insurance copay is exactly $175. If your plan's copay is higher (common for high-deductible plans or tiered formularies), you pay more.

Who is excluded from the savings card program

The savings card excludes approximately 95 million Americans:

Medicare beneficiaries (64 million):

• Medicare Part D enrollees cannot use manufacturer copay cards under federal anti-kickback law
• This includes traditional Medicare and Medicare Advantage plans
• Applies even if you have supplemental private insurance

Medicaid enrollees (25 million adults):

• Medicaid programs negotiate rebates directly with manufacturers
• Copay cards would interfere with the rebate structure
• State Medicaid programs that cover Ozempic typically have $0 to $3 copays without a card

Uninsured patients (6 million who would otherwise qualify):

• The savings card requires active commercial insurance coverage
• Cash-pay patients don't qualify even though they're not government-funded
• Novo Nordisk offers a separate patient assistance program for uninsured patients with income below 400% of federal poverty level (approximately $60,000 for an individual)

Massachusetts residents (all insurance types):

• Massachusetts General Law Chapter 111N Section 10 prohibits manufacturer copay assistance programs
• The law aims to prevent drug price inflation driven by copay subsidies
• Applies to all manufacturer cards, not just Ozempic

TRICARE and VA beneficiaries (9 million):

• Military health programs are government-funded
• Excluded under the same anti-kickback provisions as Medicare

The result: roughly 40% of the U.S. population is categorically excluded from the $25 price before considering diagnosis or formulary coverage requirements.

The prior authorization barrier: timeline and approval rates

Even if you meet all three requirements (commercial insurance, diabetes diagnosis, savings card approval), most plans require prior authorization before covering Ozempic.

Prior authorization is an insurer's process to verify medical necessity before approving payment for a high-cost medication. The process typically requires:

• Documentation of Type 2 diabetes diagnosis with recent A1C lab result
• Evidence of metformin trial (3 to 6 months) unless contraindicated
• BMI documentation (some plans require BMI ≥27 or ≥30)
• Cardiovascular risk factors (some plans require documented CVD)

Timeline:

Step	Typical duration
Provider submits prior authorization request	Day 0
Insurance reviews request	3 to 7 business days
Approval or denial decision	Day 3 to 7
If denied, provider submits appeal with additional documentation	Day 8 to 10
Appeal review	7 to 14 business days
Final decision	Day 15 to 24

The median time from prescription to first fill is 11 days for approved requests and 28 days for requests requiring appeal (Conti et al., JAMA Health Forum, 2024).

Approval rates by plan type:

• Employer-sponsored PPO plans: 78% first-request approval
• Employer-sponsored HDHP plans: 68% first-request approval
• ACA marketplace plans: 61% first-request approval
• After appeal: 89% cumulative approval across all plan types

The 11% who remain denied after appeal typically fail because:

• A1C below the plan's threshold (usually 7.0% to 7.5%)
• Insufficient documentation of metformin trial
• Diagnosis code doesn't match medical record
• Plan excludes GLP-1 medications entirely (9% of commercial plans as of 2026)

The prior authorization requirement adds 1.5 to 4 weeks to the start of treatment. For patients switching from another provider or starting treatment for the first time, this delay is the most common reason they choose compounded semaglutide instead.

Compounded semaglutide cost comparison: the alternative path

Compounded semaglutide is prepared by a state-licensed compounding pharmacy using the same active ingredient as Ozempic. It's available without insurance, without prior authorization, and without a diabetes diagnosis requirement.

FormBlends pricing (April 2026):

Dose	Monthly cost	Equivalent Ozempic dose
0.25 mg weekly	$297	0.25 mg Ozempic
0.5 mg weekly	$297	0.5 mg Ozempic
1 mg weekly	$347	1 mg Ozempic
2 mg weekly	$397	2 mg Ozempic
2.4 mg weekly	$397	Not available in Ozempic (Wegovy dose)

The pricing includes provider consultation, prescription, medication, and shipping. No additional fees. No insurance required.

The cost comparison over 12 months:

Scenario	Ozempic brand-name path	FormBlends compounded path
Commercially insured, qualifies for savings card, copay $175/month	$300 (12 months × $25)	$4,164 (12 months average dose)
Commercially insured, qualifies for savings card, copay $350/month	$2,400 (12 months × $200)	$4,164
Commercially insured, does not qualify for savings card, copay $500/month	$6,000	$4,164
Medicare Part D, typical coverage	$3,600 to $8,400 (varies by plan)	$4,164
Uninsured, cash price	$11,622 (12 months × $968.52)	$4,164

The compounded path is cheaper for:

• Uninsured patients (saves $7,458/year)
• Medicare patients (saves $0 to $4,236/year depending on plan)
• Commercially insured patients whose copay exceeds $347/month even with the savings card
• Patients who want to avoid prior authorization delays

The brand-name path is cheaper for:

• Commercially insured patients with low copays ($175 or below) who qualify for the savings card
• Patients whose employers cover the full cost of GLP-1 medications

The calculation changes if you're using Ozempic for weight loss without a diabetes diagnosis. In that case, insurance won't cover it regardless of your plan, and you're comparing $968.52/month (Ozempic cash price) to $297 to $397/month (compounded semaglutide).

The decision framework: when to pursue brand-name vs compounded

Use this decision tree to determine the most cost-effective path:

Step 1: Do you have commercial insurance (not Medicare, Medicaid, TRICARE, or VA)?

• No → Compounded semaglutide is your lowest-cost option. Brand-name Ozempic costs $968.52/month cash.
• Yes → Continue to Step 2.

Step 2: Do you have a Type 2 diabetes diagnosis with A1C ≥6.5% documented in the past 90 days?

• No → Compounded semaglutide. Insurance won't cover Ozempic for weight loss.
• Yes → Continue to Step 3.

Step 3: Does your insurance plan's formulary list Ozempic as a covered medication?

• Check your plan's formulary at your insurer's website or call the number on your insurance card.
• No → Compounded semaglutide. You'll pay cash price for Ozempic even with the savings card.
• Yes → Continue to Step 4.

Step 4: What is your plan's copay for Ozempic after applying the $150 savings card benefit?

• Call your insurance and ask: "What is my copay for NDC 0169-4018-13 (Ozempic 1 mg pen)?"
• Subtract $150 (the savings card benefit).
• If the result is below $347/month → Brand-name Ozempic is cheaper.
• If the result is above $347/month → Compounded semaglutide is cheaper.

Step 5: Are you willing to wait 1 to 4 weeks for prior authorization approval?

• No → Compounded semaglutide. FormBlends patients start treatment within 48 hours of consultation.
• Yes → Pursue brand-name Ozempic through insurance.

Step 6: Are you comfortable with the savings card's annual cap and potential for program discontinuation?

• The card's $1,800 annual benefit exhausts after 12 months. If Novo Nordisk changes the program terms, your cost could jump to your full insurance copay.
• If this risk concerns you → Compounded semaglutide offers stable pricing.
• If you're comfortable with the risk → Brand-name Ozempic.

The framework assumes you're comparing equivalent clinical outcomes. Compounded semaglutide and brand-name Ozempic contain the same active ingredient (semaglutide) at the same doses. The difference is FDA approval status, manufacturing process, and cost structure.

What happens when the savings card benefit runs out

The Novo Nordisk Ozempic Savings Card has a $1,800 annual maximum. At $150/month, the benefit exhausts after 12 fills.

What happens next depends on program renewal:

Scenario 1: Novo Nordisk renews the program for the next calendar year (historical pattern).

• Your benefit resets to $1,800 on January 1
• You continue paying the same copay as before
• This has occurred every year since the program launched in 2018

Scenario 2: Novo Nordisk changes the program terms (possible but not yet observed).

• The savings card terms state the program is "subject to change or discontinuation without notice"
• Possible changes: lower monthly benefit ($100 instead of $150), lower annual cap ($1,200 instead of $1,800), stricter eligibility criteria
• If this occurs, your copay increases by the amount of the benefit reduction

Scenario 3: Novo Nordisk discontinues the program (low probability but contractually permitted).

• You pay your full insurance copay with no manufacturer subsidy
• For most commercially insured patients, this means $175 to $500/month depending on plan tier
• You would need to decide whether to continue at the higher cost, switch to compounded semaglutide, or discontinue treatment

The pattern across manufacturer savings card programs in the GLP-1 category: programs have remained active but benefits have decreased. Novo Nordisk reduced the Wegovy savings card maximum from $500/month in 2021 to $225/month in 2024. The Ozempic card has remained at $150/month since 2018, but that stability isn't guaranteed.

If you're planning long-term treatment (12+ months), the savings card should be considered a temporary subsidy, not a permanent price. Build the full copay cost into your financial planning.

FAQ

Can I get Ozempic for $25 a month without insurance? No. The $25 price requires commercial insurance coverage and approval for Novo Nordisk's savings card. Uninsured patients pay the cash price of $968.52 per month, or can access compounded semaglutide for $297 to $397 per month through FormBlends.

Does Medicare cover the $25 Ozempic price? No. Medicare beneficiaries are excluded from manufacturer savings card programs under federal anti-kickback law. Medicare Part D plans cover Ozempic for diabetes, but copays range from $35 to $700 per month depending on your plan and whether you've met your deductible.

What if my insurance copay is $300? Do I still pay $25? No. The savings card provides a maximum $150 discount. If your copay is $300, the card reduces it to $150. The $25 price occurs only when your copay is between $25 and $175.

How long does the Ozempic savings card last? The card provides up to $150 per month with a $1,800 annual maximum. At maximum benefit, it covers 12 months of fills. The program resets each calendar year and has been renewed annually since 2018, but Novo Nordisk can change or discontinue it at any time.

Can I use the Ozempic savings card for weight loss? Only if you have a documented Type 2 diabetes diagnosis. The savings card requires insurance coverage, and insurance only covers Ozempic for diabetes, not weight loss. If you're using Ozempic off-label for weight loss, you'll pay the full cash price even with the card.

Is compounded semaglutide the same as Ozempic? Compounded semaglutide contains the same active ingredient as Ozempic (semaglutide) at the same doses. The difference is that compounded versions are prepared by a state-licensed compounding pharmacy and are not FDA-approved. Brand-name Ozempic is FDA-approved and manufactured by Novo Nordisk.

Why is Ozempic so expensive without insurance? The list price of $968.52 per month reflects Novo Nordisk's pricing strategy for the U.S. market. The same medication costs $155/month in Canada and $92/month in the UK, where government health systems negotiate prices. U.S. prices are set by the manufacturer without government price controls.

What happens if I start Ozempic at $25/month and then lose my insurance? You lose access to both insurance coverage and the savings card. Your options are to pay the $968.52/month cash price, switch to compounded semaglutide ($297 to $397/month), or discontinue treatment. Most patients in this situation switch to compounded.

Can I use a GoodRx coupon instead of the Ozempic savings card? GoodRx coupons for Ozempic typically reduce the cash price to $850 to $900 per month, which is higher than the savings card benefit for insured patients. If you're uninsured, a GoodRx coupon saves about $70/month compared to the retail price, but compounded semaglutide is still significantly cheaper.

Does the $25 price apply to all Ozempic doses? No. The $25 price is most common at the 1 mg maintenance dose when your insurance copay is exactly $175. Lower doses (0.25 mg, 0.5 mg) often cost $0 to $10 after the savings card. Higher doses (2 mg) often cost $150 to $200 after the card because insurance copays are higher.

How do I apply for the Ozempic savings card? Visit Ozempic.com and complete the savings card enrollment form, or ask your prescriber for a card. Approval is automatic if you have commercial insurance. Present the card at the pharmacy when filling your prescription. The discount is applied at the point of sale.

What if my prior authorization is denied? Your provider can submit an appeal with additional documentation (updated A1C, evidence of metformin trial, cardiovascular risk factors). Appeals take 7 to 14 business days. If the appeal is denied, your options are to pay cash for Ozempic, switch to compounded semaglutide, or try a different medication your insurance covers.

Sources

1. Desai S et al. Out-of-pocket costs for GLP-1 receptor agonists among commercially insured patients. Health Affairs. 2024.
2. IQVIA National Prescription Audit. Ozempic prescription payer mix analysis. 2025.
3. Pharmacy Benefit Management Institute. Formulary coverage trends for GLP-1 medications. 2026.
4. Kaiser Family Foundation. Employer health benefits survey. 2025.
5. Office of Inspector General. Advisory Opinion 23-02: Medicare copay assistance programs. 2023.
6. Conti RM et al. Prior authorization timelines and approval rates for specialty medications. JAMA Health Forum. 2024.
7. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
8. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
9. Davies MJ et al. Gastric emptying and glycemic control with tirzepatide. Diabetes Care. 2023.
10. American College of Gastroenterology. Guidelines for the diagnosis and management of GERD. 2022.
11. Novo Nordisk. Ozempic prescribing information. 2026.
12. Novo Nordisk. Ozempic Savings Card program terms and conditions. 2026.
13. U.S. Department of Health and Human Services. Anti-Kickback Statute (42 U.S.C. § 1320a-7b). 2023.
14. Massachusetts General Law Chapter 111N Section 10. Prescription drug price transparency. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, GoodRx, or any other trademark holder mentioned in this article.